Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 453-456 , October 2003

Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer

References 

  1. Fisher B, Foster R, Gardner B, et al.  Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer. 1983;52:1551–1557
  2. Saez RA, McGuire WL, Clark GM, et al.  Prognostic factors in breast cancer. Sem. Surg. Oncol. 1989;5:102–110
  3. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 1986;4:1162–1170
  4. Wood W, Budman D, Korzun A, et al.  Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med. 1994;330:1253–1259
  5. Norton L, Simon R. The Norton–Simon hypothesis revisited. Cancer Treat. Res. 1986;70:163–169
  6. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48:7067–7071
  7. Gilewski T, Surbone A, Dang CT, Norton L. Cytokinetics. In:  Holland JF,  Frei E,  Bast RC, et al. editor. Cancer Medicine. fifth ed.. Baltimore: Williams and Wilkins; 2000;p. 491–519
  8. Skipper HE. Laboratory models: the historical perspective. Cancer Treat. Rep. 1986;70:3
  9. Bonadonna G, Zambette M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more tan three positive nodes. JAMA. 1995;273:542–547
  10. Green MC, Buzdar AU, Smith S, et al.  Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week P therapy followed by FAC: Final results of a prospective phase III randomized trial. Proc. Am. Soc. Clin. Oncol. 2002;21:35a; (abstr 135)
  11. Untch M, Konecny G, Ditsch N, et al.  Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized trial AGO study. Proc. Am. Clin. Oncol. 2002;21:34a; (abstr 133)
  12. Therasse P, Mauriac L, Jassem J, et al.  Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with dose-intensified epirubicin and cyclophosphamide plus filgrastim in locally advanced breast cancer. A EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 2003;21:843–850
  13. Jackisch C, Von Minckwitz G, Rabb G, et al.  Primary endpoint analysis of the Geparduo-study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential Adriamycin/docetaxel combination in operable breast cancer. Breast Cancer Res. Treat. 2002;76:s50; (suppl, abstr 152)
  14. Hudis C, Seidman A, Baselga J, et al.  Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for respectable high-risk breast cancer: feasibility and efficacy. J. Clin. Oncol. 1999;17:93–100
  15. Hudis C, Fornier M, Riccio L, et al.  5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J. Clin. Oncol. 1999;17:1118–1126
  16. Fornier MN, Seidman AD, Theodoulou M, et al.  Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive primary breast cancer. Clin. Cancer Res. 2001;7:3934–3941

☆ Sources of funding: Not specified.

☆☆ For correspondence: Marc L. Citron, MD, ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042; E-mail: mcitron@prohealthcare.com.

★ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(03)00164-6

doi: 10.1016/S0305-7372(03)00164-6

Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 453-456 , October 2003

Article Tools